Combined Therapy With Desferrioxamine and Deferiprone: A New Protocol for Iron Chelation in Thalassemia
Emanuela D′Angelo, Nadia Mirra, A. A. Rocca, V. Carnelli
Deferiprone (DFO) at the standard daily dose of 75 mg/kg was given to 13 transfusion-dependent patients with thalassemia in whom conventional desferrioxamine (DFX) therapy had proven ineffective and caused adverse side effects. In six patients, serum ferritin and alanine aminotransferase levels decreased …
it (code pays fourni par la source)